The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, provided ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

Our editors also may be in touch with follow-up questions. Ozempic is a brand-name, injectable semaglutide medication. It’s prescribed, alongside dietary changes and exercise, to adults with ...

(See the dosing chart in the “Strattera dosage overview” section.) For more information about Strattera’s dosage for children, talk with your child’s doctor or a pharmacist. Strattera ...

Until you consider a Morgan Stanley projection that says by 2035, 24 million people will be taking Ozempic, Wegovy, or another GLP-1. Which makes sense. A study published in the Journal of the ...